Navigation Links
STAAR Surgical Reports 33% Third Quarter Revenue Growth
Date:10/28/2008

taar - 4,000

Other assets 1,028 620

Total assets $55,661 $54,179

Accounts payable $6,363 $4,823

Deferred income taxes - current 105 102

Obligations under capital leases -

current 896 822

Line of credit 1,880 -

Other current liabilities 6,932 5,541

Total current liabilities 16,176 11,288

Notes payable - long-term, net of

discount 4,346 4,166

Obligations under capital leases -

long-term 1,184 1,311

Deferred income taxes - long-term 690 570

Other long-term liabilities 1,715 619

Total liabilities 24,111 17,954

Series A redeemable convertible

preferred stock 6,764 -

Stockholders' equity - net 24,786 36,225

Total liabilities, convertible

preferred stock and equity $55,661 $54,179

STAAR Surgical Company

Condensed Consolidated Statements of Cash Flows

(in 000's)

Unaudited

Nine Months Ended

September 26, September 28,

2008 2007

Cash flows from operating activities:

Net loss $(13,735) $(11,708)

Adjustments to reconcile net loss

to net cash used in operating

activities:

Depreciation of property, plant

and equipment 2,055 1,463

Amortization of intangibles 62
'/>"/>

SOURCE STAAR Surgical Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. STAAR Surgical to Present at the Noble Financial Equity Conference
2. STAAR Surgicals Collamer(R) IOL and Elastimide(R) IOL Each Recognized with New Technology Intraocular Lens Classification
3. STAAR Surgicals LASIK Alternative Expands U.S. Market Gains
4. STAAR Surgical Reports Solid First Quarter Progress
5. STAAR Surgical Announces First Quarter 2008 Earnings Release Date and Conference Call
6. STAAR Surgical Plans Major Presence at ASCRS
7. STAAR Surgical Reports Fourth Quarter and Year End Results
8. STAAR Surgicals Visian ICL Procedure Performed Live on NBCs Today show
9. STAAR Surgical Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call
10. STAAR Surgical to Present at the Tenth Annual Needham Growth Conference
11. STAAR Surgical Completes $5M Debt Financing for Purchase of Japanese Joint Venture
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10DSS Research Announces Senior Health Risk Assessment 28SrHRA 29 28TM 29 58537 1DSS Research Announces Senior Health Risk Assessment 28SrHRA 29 28TM 29 58537 2Pan American Life Insurance Group Plans to Complete Coverage in Central America With Entry Into Costa Rica 3B Company Files Request for Authorization 58534 1Pan American Life Insurance Group Plans to Complete Coverage in Central America With Entry Into Costa Rica 3B Company Files Request for Authorization 58534 2Sport Science Lab Maintains That Injury to USC Football Player is Symptomatic of the Dangers of Conventional Weight Training 58530 1Sport Science Lab Maintains That Injury to USC Football Player is Symptomatic of the Dangers of Conventional Weight Training 58530 2